Investors
The Opportunity in Pharmaceutical Access
Haven Life Sciences Inc. is building the compliance-first infrastructure layer for global pharmaceutical procurement.
A Large, Underserved Market
$1.2 trillion
Global pharmaceutical market (2024)
300%+
Increase in drug shortages over the past decade across North American healthcare systems
2B+
People worldwide affected by inadequate access to essential medicines
Pharmaceutical procurement is a $500B+ market characterized by opacity, fragmentation, and inefficiency. Haven is building the technology and supply network to fix this.
Five Phases of Growth
Medicine Access Platform
Active ✓Source shortage-affected medicines from trusted suppliers and sell through a controlled B2B system. Prove that qualified buyers will pay for reliable access to shortage drugs through a compliant procurement workflow.
Manufacturing Partners
Build stronger supply deals with qualified manufacturing partners after demand is proven. Move from spot sourcing to preferred partnership agreements with GMP-certified manufacturers.
Haven-Branded Products
Create selected Haven-branded medicines where there is repeat demand and a clear market need. Own the product identity and margin, not just the supply relationship.
Own Manufacturing & R&D
Build or acquire manufacturing capacity only when it is better than outsourcing. Enter manufacturing only after brand trust and volume are proven.
Medical Technology
Expand into devices, diagnostics, digital health, automation, and deep tech research. Use the procurement network as the distribution foundation for adjacent healthcare technology.
Decision Gate Criteria
Before advancing to the next phase, Haven's leadership answers: Is there a real shortage problem? Can Haven legally source and sell? Does the supplier prove quality? Will buyers buy? Do the numbers work after all costs? Can the process be repeated?
Why Haven Wins
Technology-driven procurement systems
Strategic global sourcing partnerships
Focus on supply reliability
Customer-centric healthcare solutions
Long-term vertical integration strategy
Commitment to improving access to essential medicines